|
111 |
Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
Enthalten in Indian journal of gastroenterology Bd. 41, 15.11.2022, Nr. 5, date:10.2022: 446-455
|
|
|
|
112 |
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study
Enthalten in BioDrugs Bd. 38, 22.11.2023, Nr. 1, date:1.2024: 121-131
|
|
|
|
113 |
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
Enthalten in BioDrugs Bd. 34, 23.9.2020, Nr. 5, date:10.2020: 681-694
|
|
|
|
114 |
Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review
Enthalten in BioDrugs Bd. 32, 22.5.2018, Nr. 3, date:6.2018: 193-199
|
|
|
|
115 |
Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with rheumatoid arthritis: a 12-month observational study
Enthalten in Advances in rheumatology Bd. 65, 10.10.2025, Nr. 1, date:12.2025: 1-5
|
|
|
|
116 |
Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study
Enthalten in BioDrugs Bd. 35, 16.10.2021, Nr. 6, date:11.2021: 735-748
|
|
|
|
117 |
Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin
Enthalten in Diabetes therapy Bd. 13, 1.6.2022, Nr. 7, date:7.2022: 1299-1310
|
|
|
|
118 |
Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin
Enthalten in Diabetes therapy Bd. 12, 11.1.2021, Nr. 2, date:2.2021: 557-568
|
|
|
|
119 |
Erythropoietin-induced Treatment Costs in Patients Suffering from Renal Anemia – A Comparison between Biosimilar and Originator Drugs
Enthalten in Das Gesundheitswesen Bd. 76, 2014, Nr. 11: e79-e84
|
|
|
|
120 |
Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial
Enthalten in Scientific reports Bd. 14, 22.10.2024, Nr. 1, date:12.2024: 1-12
|
|
Administration
